× Medicines Discovery Catapult

Our interconnected platforms are kept at the scientific leading-edge through constant, technology-driven innovation, and they include:

Cell Model Analysis and Validation

We can test your lead molecule in our suite of human, in vitro cell models (currently focussed on neuroscience, liver, cardiac and oncology) to demonstrate efficacy in healthy and disease models or evaluate potential toxicity.

Alternatively, we can help to characterise and validate your novel cell model or technology in a real-world medicines discovery setting.

Key technologies include:

  • Organ-on-a-chip platforms
  • Mass spectrometry and mass spectrometry imaging
  • Advanced microscopy
  • Transcriptomics and biomarker signatures

Target & Pathway Engagement

We can help you build a platform of evidence linking your drug molecule to modulation of its target protein and downstream biological effect, in relevant in vitro and in vivo assay systems.

Key technologies include:

  • Advanced microscopy
  • Mass spectrometry and mass spectrometry imaging
  • Transcriptomics and biomarker signatures
  • Preclinical Imaging

Together with a suite of molecular and cell biology methods.

Drug Delivery & Biodistribution

We can help you understand your lead molecule or delivery technology by applying in vivo imaging to measure the biodistribution of labelled molecules (small molecules, antibodies and ADCs, nanomedicines) in real-time. This can assess the impact of different delivery methods on biodistribution and biological effects.

We can also apply mass spectrometry imaging and multiphoton imaging to measure the distribution of unlabelled molecules (and drug metabolites) in tissue sections.

Biomarkers

We can identify novel biomarkers to track the impact of your proposed new lead molecule, or test known biomarkers to support translation of your potential therapeutic. For example, biomarkers to enable patient stratification, demonstrate efficacy, or monitor safety endpoints.

Key assay platforms include:

  • Spatial biomarker analysis using molecular pathology
  • Spatial transcriptomics within tissue sections
  • Experience in advanced diagnostic screening in our Lighthouse Lab
  • Mass spectrometry imaging
  • Bulk analysis of samples using transcriptomics and mass spectrometry

Technology Innovation

We have established a suite of ‘hard-to-access’ assay & bioanalytical technologies that can be applied to address your project challenges.

Key platforms include:

  • Preclinical small animal imaging including PET
  • Mass spectrometry
  • Advanced microscopy
  • Molecular pathology

In addition, we have established access to pre-commercial technologies through collaborative partnerships with innovators, and we are always on the lookout for new opportunities of this type.

A Strategy for Success

Working in close collaboration with you, the Discovery team will define a bespoke project plan, using industry-leading insight and experience to address your project challenges and increase your chance of success.

We can provide guidance where you may need it, find the right partners to help you, fill gaps in your existing project plan and help manage your project delivery.

Lightening the Load

The advantage of partnering with others for some or all of your R&D is twofold: Firstly, you get to keep your internal team lean, agile, focused and cost-effective. Secondly, you gain access to specialist scientific experts and costly technologies – in a flexible manner as you need it.

Whether you need to generate complex assay data, source samples or develop a novel biomarker as a potential companion diagnostic, MDC’s Discovery team can offer seamless support.

Finding the Right Partners

The UK is rich with resources in medicines R&D. But the wealth of talent and technology available can feel overwhelming to those with limited time and resources to explore it. The Discovery team will help you navigate this complex landscape, understand the skills and expertise that you require, and then connect with the people and organisations that can provide them.

Our network of partners spans both the private and public sectors, taking in CROs, universities, research institutes and the NHS. It’s a network comprised of some of the sharpest minds that UK medicines discovery has to offer.